Avadel Pharmaceuticals plc (NASDAQ: AVDL) is -22.73% lower on its value in year-to-date trading and has touched a low of $10.39 and a high of $19.09 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AVDL stock was last observed hovering at around $11.59 in the last trading session, with the day’s loss setting it -0.68%.
Currently trading at $10.91, the stock is -20.96% and -19.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.08 million and changing -5.87% at the moment leaves the stock -28.37% off its SMA200. AVDL registered -0.09% loss for a year compared to 6-month loss of -29.57%. The firm has a 50-day simple moving average (SMA 50) of $13.4856 and a 200-day simple moving average (SMA200) of $15.2308.
The stock witnessed a -21.62% gain in the last 1 month and extending the period to 3 months gives it a -32.45%, and is -31.56% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.74% over the week and 6.01% over the month.
Avadel Pharmaceuticals plc (AVDL) has around 154 employees, a market worth around $1.05B and $138.16M in sales. Fwd P/E is 20.11. Profit margin for the company is -52.53%. Distance from 52-week low is 5.00% and -42.85% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.79%).
with sales reaching $53.07M over the same period.The EPS is expected to grow by 76.06% this year, but quarterly earnings will post 515.08% year-over-year. Quarterly sales are estimated to grow 172.80% in year-over-year returns.
Avadel Pharmaceuticals plc (AVDL) Top Institutional Holders
231.0 institutions hold shares in Avadel Pharmaceuticals plc (AVDL), with institutional investors hold 84.07% of the company’s shares. The shares outstanding are 89.83M, and float is at 87.75M with Short Float at 10.77%. Institutions hold 80.06% of the Float.
The top institutional shareholder in the company is VIVO CAPITAL, LLC with over 3.97 million shares valued at $55.85 million. The investor’s holdings represent 4.332% of the AVDL Shares outstanding. As of 2024-06-30, the second largest holder is TRI LOCUM PARTNERS LP with 1.19 million shares valued at $16.72 million to account for 1.2973 of the shares outstanding. The other top investors are BIOIMPACT CAPITAL LLC which holds 0.78 million shares representing 0.8542% and valued at over $11.01 million, while KNOLL CAPITAL MANAGEMENT, LLC holds 0.6544 of the shares totaling 0.6 million with a market value of $8.44 million.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
The most recent transaction is an insider purchase by MCHUGH THOMAS S, the company’s Chief Financial Officer. SEC filings show that MCHUGH THOMAS S bought 2,000 shares of the company’s common stock on Jan 16 ’24 at a price of $14.50 per share for a total of $29000.0. Following the purchase, the insider now owns 80500.0 shares.
Avadel Pharmaceuticals plc disclosed in a document filed with the SEC on Dec 28 ’23 that McCamish Mark Anthony (Director) sold a total of 75,000 shares of the company’s common stock. The trade occurred on Dec 28 ’23 and was made at $14.53 per share for $1.09 million. Following the transaction, the insider now directly holds 67025.0 shares of the AVDL stock.
